DSM-Firmenich AG

DSFIR: XAMS (NLD)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
LOCK|xFLOCK|cPcLOCK|Ykn$Qg

DSM-Firmenich Earnings: Sales Growth Ahead of Peers Reinforces Outlook; Shares Fairly Valued

DSM-Firmenich reported organic sales growth accelerating to 6% in the second quarter, outpacing its own full-year guidance and Vara-compiled consensus. EBITDA margin also saw a slight increase. Shares rose about 13% on July 30.

Sponsor Center